Patents show all

20Applications8Issued

Clinical Trials show all

8Phase 22Phase 1

SEC Filings show all

D10

SEC Form D Funding Events

DateOfferedSoldType
2015-03-24$14,603,554$14,462,851Equity, Other
2015-02-17$9,048,000$8,740,630Equity, Other
2014-11-20$7,257,161$7,240,631Equity, Other
2014-09-05$7,117,217$6,913,123Equity, Other
2014-04-11$5,872,773$5,813,123Equity, Other
2013-05-14$5,372,769$5,313,122Equity, Other
2012-08-29$5,000,000$4,557,568Equity, Other
2010-09-20$8,300,000$8,300,000Equity, Other
2009-01-21UnknownUnknownOther (Paper Filing)

Key Executives

  • David Cory
    Executive Officer, Director
  • Ed Engleman
    Director
  • Jeffrey Glenn
    Director
  • Nina Kjellson
    Director
  • Paul Truex
    Director
  • Keith Vendola
    Executive Officer
  • Glen Sato
    Executive Officer
  • Wenjin Yang
    Executive Officer